STIO is an Egyptian family-owned Private Joint Stock company established in 2016 with authorized capital of EGP 500 million and paid-in capital EGP 100 million.

STIO has 10 registered products and 16 pipeline products under registration (2 of them are biosimilars).

At Stio, healthcare is more than just medicine—it’s about creating solutions that heal, restore, and transform lives. We focus on delivering essential medicines that address critical healthcare needs, with a commitment to ensuring quality and accessibility for all.

Rooted in innovation and purpose, Stio specializes in advanced therapies designed to support patients in cardiovascular health, respiratory care, sedation, and pain management. Since our founding in 2017, we have been driven by a vision to localize the production of high-quality pharmaceuticals while meeting the specific needs of Egypt, Africa, and the Middle East.

By combining cutting-edge science with compassionate care, we are striving to be the partner of choice for a healthier tomorrow.